Bristol-Myers, Samsung BioLogics expand drug manufacturing agreement PBR Staff Writer Published 23 April 2014 Bristol-Myers Squibb (BMS) and Samsung BioLogics are expanding their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several BMS biologic medicines at its Incheon manufacturing site. Both the companies' have not disclosed the financial terms of the agreement. In July 2013, both the firms have entered into their first manufacturing agreement to collaborate in the production of a single commercial antibody cancer drug substance. BMS president of Global Manufacturing & Supply Lou Schmukler said biologic medicines that treat serious diseases are an integral part of the company's specialty care portfolio and R&D pipeline."The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients," Schmukler said. Samsung BioLogics president and CEO TH Kim said, "Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production. "Under the deal, Samsung brings global biopharmaceutical capability through its fully-integrated production facilities that provide process development, drug substance manufacturing as well as drug product fill & finish services at one location. Apart from its current biologics manufacturing facility in Incheon, Korea, BMS is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.
No comments:
Post a Comment